Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

24.44
+0.55002.30%
Post-market: 24.44-0.0040-0.02%19:39 EDT
Volume:5.07M
Turnover:123.57M
Market Cap:4.03B
PE:-7.70
High:24.87
Open:23.92
Low:23.70
Close:23.89
52wk High:25.00
52wk Low:8.88
Shares:165.03M
Float Shares:165.00M
Volume Ratio:1.31
T/O Rate:3.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1760
EPS(LYR):-3.4740
ROE:-58.89%
ROA:-32.70%
PB:4.66
PE(LYR):-7.04

Loading ...

Press Release: Dyne Therapeutics Appoints Barry Greene to Board of Directors

Dow Jones
·
Jun 23

Dyne Therapeutics grants new hires stock options for 126,000 shares, RSUs for 40,100 shares

Reuters
·
Jun 19

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 19

Dyne Therapeutics Shares Rise After Amendment to Debt Facility

Dow Jones
·
Jun 17

Dyne Therapeutics, - Adds up to $125 Mln in Additional Borrowing Capacity

THOMSON REUTERS
·
Jun 17

Press Release: Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

Dow Jones
·
Jun 17

Insider Makes Bold New Move on Dyne Therapeutics Stock

TIPRANKS
·
Jun 10

Dyne Therapeutics director Brian S. Posner reports $33,880 common share purchase

Reuters
·
Jun 10

Dyne Therapeutics (DYN) Is Down 9.8% After Doubling Share Authorization Amid Key Rare Disease Milestones

Simply Wall St.
·
Jun 09

Dyne Therapeutics Expands Share Authorization After Stockholder Approvals

TIPRANKS
·
Jun 09

Dyne Therapeutics shareholders approved charter amendment raising authorized common shares to 400 million

Reuters
·
Jun 09

Dyne Therapeutics Insider Makes Bold New Move in Company Stock

TIPRANKS
·
Jun 06

Dyne Therapeutics director Brian S. Posner reports purchase of 2,500 common shares worth $43,700

Reuters
·
Jun 06

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Arcus Biosciences (RCUS) and Dyne Therapeutics (DYN)

TIPRANKS
·
Jun 04

Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Dyne Therapeutics (DYN) and Argenx Se (ARGX)

TIPRANKS
·
Jun 04

Analyst Reiterates Buy on Dyne Therapeutics, Maintains $44 Price Target on De-Risked Late-Stage Pipeline and Regulatory Momentum

TIPRANKS
·
Jun 04

Dyne Therapeutics completes enrollment in ACHIEVE trial of zeleciment basivarsen

TIPRANKS
·
Jun 03

Dyne Fully Enrolls ACHIEVE Trial for DM1 Therapy

TIPRANKS
·
Jun 03

Dyne Therapeutics completes enrollment in ACHIEVE trial expansion cohort for z-basivarsen in DM1

Reuters
·
Jun 03

Dyne Therapeutics, - Registrational Expansion Cohort Enrolled 71 Participants; Topline Data Planned for Q1 2027

THOMSON REUTERS
·
Jun 03